)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
G1 Therapeutics
G1 Therapeutics (GTHX) investor relations material
G1 Therapeutics has been acquired
G1 Therapeutics Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary8 Aug, 2024
Executive summary
Net product sales for COSELA increased 43% year-over-year to $15.8 million for Q2 2024, with double-digit quarter-over-quarter growth in vial volume and net revenue.
License revenue dropped to $0.7 million from $31.3 million in Q2 2023, reflecting the absence of prior year one-time payments.
Net loss for Q2 2024 was $5.5 million, compared to net income of $8.7 million in Q2 2023, due to lower license revenue.
Pending acquisition by Pharmacosmos for $7.15 per share in cash, expected to close in late Q3 2024.
Announced two license agreements for lerociclib, providing upfront payments, milestones, and royalties.
Financial highlights
Q2 2024 revenues: $16.5 million (product sales $15.8M, license revenue $0.7M); Q2 2023: $42.4 million (product sales $11.1M, license revenue $31.3M).
Operating expenses decreased to $20.1 million in Q2 2024 from $30.9 million in Q2 2023, mainly from lower R&D and SG&A costs.
Net loss per share was $(0.10) (basic and diluted) for Q2 2024, versus $0.17 (basic) and $0.14 (diluted) in Q2 2023.
Cash, cash equivalents, and marketable securities totaled $60.7 million as of June 30, 2024.
Accumulated deficit reached $795.7 million as of June 30, 2024.
Outlook and guidance
Reaffirmed 2024 net COSELA revenue guidance of $60M–$70M.
Expects 2024 operational expenses to be 25%–30% below 2023 levels.
Management expects to achieve profitability in the second half of the next fiscal year.
Cash runway expected to fund operations into Q3 2025 and cover covenants for at least 12 months.
No new R&D activities planned; focus remains on global commercialization of COSELA.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from G1 Therapeutics
G1 Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
G1 Therapeutics Inc is a biopharmaceutical company developing therapies for the treatment of cancer. The company focuses on small-molecule drugs designed to preserve bone marrow and enhance the effectiveness of chemotherapy. Its operations span research, clinical development, and regulatory affairs. The company is headquartered in Research Triangle Park, North Carolina, and its shares are listed on the NASDAQ.